PRO-PHARMACEUTICALS NAMES NOTED PHYSICIAN DR. GILBERT S. OMENN TO SCIENTIFIC ADVISORY BOARD
Newton, MA – July 14, 2009 – Pro-Pharmaceuticals, Inc. (OTCBB: PRWP), a developer of carbohydrate-based targeted therapeutic compounds to treat cancers and fibrosis, today named Dr. Gilbert S. Omenn to its Scientific Advisory Board.
“My research in cancer biology and chemoprevention piqued my interests in Pro-Pharmaceuticals’ novel technology approach to treating cancers with carbohydrate compounds. I look forward to working with the team to further the Company’s medical strategy and product development efforts,” said Dr. Omenn.
“We are delighted to welcome Dr. Omenn to our Scientific Advisory Board, as he brings a wealth of experience, notable credentials and shares our commitment to developing a new generation of oncology and fibrosis treatments,” said Theodore Zucconi, Ph.D., Chief Executive Officer, Pro-Pharmaceuticals, Inc. “Dr. Omenn’s clinical and scientific accomplishments will be a tremendous asset as we work toward commercializing DAVANAT® and its potential to extend survival, improve quality of life and lower costs for cancer patients.”
Dr. Gilbert S. Omenn, age 67, is a director of Amgen, Inc. and Armune Biosciences, Inc. He is a Professor of Internal Medicine, Human Genetics and Public Health, and Director of the Center for Computational Medicine and Bioinformatics at the University of Michigan. He leads major research programs in proteomics and in integrative biomedical informatics. Dr. Omenn served as Executive Vice President for Medical Affairs and as Chief Executive Officer of the University of Michigan Health System during 1997-2002. Earlier, he was the Dean of the School of Public Health and Community Medicine and Professor of Medicine at the University of Washington.
Dr. Omenn is the author of more than 460 research papers and scientific reviews and author/editor of 18 books. He is a member of the Institute of Medicine of the National Academy of Sciences, the American Academy of Arts and Sciences, the Association of American Physicians, and the American College of Physicians. He served as associate director of the White House Office of Science and Technology Policy and then the Office of Management and Budget in the Carter Administration. He chaired the presidential/congressional Commission on Risk Assessment and Risk Management, served on the National Commission on the Environment, and chaired the National Academies’ Committee on Science, Engineering and Public Policy. He received the John W. Gardner Legacy of Leadership Award from the White House Fellows Association in 2004 and the Walsh McDermott Award from the Institute of Medicine in 2008. He is Vice-President of the International Human Proteome Organization. Dr. Omenn received his B.A. summa cum laude from Princeton University, M.D. magna cum laude from Harvard Medical School, and Ph.D. in genetics from the University of Washington.
DAVANAT®, Pro-Pharmaceuticals’ lead product candidate, is a carbohydrate polymer specifically formulated to interact with galectins. DAVANAT®'s mechanism of action is based on interacting with galectins which are over-expressed on the surface of solid tumors. Current research indicates that galectins affect cell development and play important roles in cancer, including tumor cell survival, angiogenesis and tumor metastasis.
Pro-Pharmaceuticals, OTCBB: PRWP, is engaged in the discovery, development and commercialization of carbohydrate therapeutics for advanced treatment of cancer and fibrosis. Initially, the product pipeline is focused on increasing the efficacy and decreasing the toxicity of chemotherapy drugs. The Company is headquartered in Newton, Mass. Additional information is available at www.pro-pharmaceuticals.com.
FORWARD LOOKING STATEMENTS: Any statements in this news release about future expectations, plans and prospects for the Company, including without limitation statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements as defined in the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations and are subject to a number of factors and uncertainties, which could cause actual results to differ materially from those described in such statements. We caution investors that actual results or business conditions may differ materially from those projected or suggested in forward-looking statements as a result of changing conditions. Readers should not place undue reliance on forward-looking statements. The forward-looking statements represent the Company’s views as of the date of this news release and should not be relied upon to represent the Company’s views as of a subsequent date. While the Company anticipates that subsequent events may cause the Company’s views to change, the Company disclaims any obligation to update such forward-looking statements.
Contact: Pro-Pharmaceuticals, Inc., Anthony D. Squeglia: 617.559.0033; email@example.com.
DAVANAT is a registered trademark of Pro-Pharmaceuticals.